该职位已失效,看看其他机会吧

区域医学顾问MSL-Oncology(成都)

1.5-2.5万·13薪
  • 成都武侯区
  • 1-3年
  • 硕士
  • 全职
  • 招1人

雇员点评标签

  • 工作环境好
  • 同事很nice
  • 团队执行强
  • 氛围活跃
  • 人际关系好
  • 交通便利
  • 晋升机会多
  • 管理人性化

职位描述

新药特药处方药
Principal Accountabilities:
  • In cooperation with medical advisor and other internal stakeholders to develop and implement national/regional MSL plan for the oncology territory.
  • Exchange knowledge by involvement in 1) information sharing with TAEs, 2) medical education for HCPs, 3) 3rd party congress and medical symposia and 4) support for interaction with payers, patient organizations and other stakeholders.
  • Generate insight by profiling and mapping TAEs, seeking advice from TAEs by individual visit or meetings, contributing to medical/brand strategy and providing information for local knowledge exchange activities.
  • Support company sponsored trials and investigator initiated trials (IIT)
  • Provide appropriate cross-functional scientific support and training, to interactive with commercial team in a non-promotional way
  • Ensure the activities and expense in align with the budget in accordance with compliance and company SOPs.
Knowledge/ Academic Qualification:
  • Master’s degree or above in clinical medicine or pharmacology, preferable with clinical practice background of oncology or neurosurgery.
Skills:
  • Fluent both in oral and written English and Chinese
  • Excellent communication and presentation skills
  • Proficiency in Basic Microsoft Word, Powerpoint and Excel.
Experience:
  • Above 2 years of Medicine relevant working,preferable with oncology or neurosurgery related background.
  • MSL or CRA in pharmaceutical medical affairs function is preferred.
  • Clinical experience is preferred
Competency:
  • Knowledge in medicine or pharmacology
  • Proactive attitude and open minded
  • Willing to undertake challenging work
  • Good team work spirit
  • Capability to trip for business purposes
查看全部

工作地点

武侯区成都市人民政府

认证资质

营业执照信息

职位发布者

HR/人事经理

立即沟通
公司Logo法国施维雅
施维雅是一家由非盈利性基金管理的国际制药公司,总部位于法国(叙雷讷),业务遍及全球150个国家。全球共计21,800名员工共同致力于推进医疗变革创新升级,为患者提供高质量药物与关键性健康解决方案。集团平均每年将20%品牌药物收入投入于药品研发。同时,集团长期与学术机构、制药企业以及生物技术公司保持开放的合作,从而加速医疗创新、惠及更多患者,创造一个可以确保所有人获得优质健康服务的世界。集团在心血管与代谢疾病、肿瘤学、神经科学以及免疫炎症四个领域的持久承诺是集团持续增长的动力。
公司主页